Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder

NCT04987658 | Completed Phase 1 FDA Drug

• 1 other identifier: ALKS 3831-A311
• Study Type: interventional
• Target: 7
• Locations: 1 country
• Sites: 2

Brief Summary

To evaluate the safety, tolerability, and pharmacokinetics of olanzapine and samidorphan in clinically stable pediatric subjects (10 to 12 years old) with Bipolar I disorder following oral administration of multiple ascending doses of OLZ/SAM

Conditions

Bipolar I Disorder

Keywords

Bipolar I Disorder; Olanzapine; Samidorphan; OLZ/SAM; ALKS 3831; Pediatric pharmacokentics; LYBALVI

Outcome Measures

Primary Outcomes (4)

• Maximum plasma concentration observed

  Up to 3 weeks

• Area under the plasma concentration-time curve over the 24-hour dosing interval

  Up to 3 weeks

• Time to reach maximum concentration

  Up to 3 weeks

• Incidence of Adverse Events

  Up to 6 weeks

Study Arms (2)

Group 1 Olanzapine/ 5 mg Samidorphan

EXPERIMENTAL

Olanzapine will be gradually increased to a target dose of 10mg/samidorphan 5mg (Range: 5-20mg Olanzapine/samidorphan 5mg)

Drug: OLZ/SAM

Group 2 Olanzapine/ 10mg Samidorphan

EXPERIMENTAL

Olanzapine will be gradually increased to a target dose of 10mg/samidorphan 10mg (Range: 5-20mg Olanzapine/samidorphan 10mg)

Drug: OLZ/SAM

Interventions

OLZ/SAM DRUG

Olanzapine and Samidorphan taken once daily over a max period of 21 days

Also known as: ALKS 3831

Group 1 Olanzapine/ 5 mg Samidorphan; Group 2 Olanzapine/ 10mg Samidorphan

Eligibility Criteria

• Age: 10 Years - 12 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Subject's parent(s)/legal guardian(s) is considered reliable by the Investigator and has agreed to provide support to the subject to ensure compliance with study treatment, visits, and protocol procedures.
• Male and female subjects between 10 and 12 years of age, inclusive.
• Subject weighs ≥70 pounds.
• Subjects who are receiving antipsychotic treatment for their medical condition, with a diagnosis of bipolar I disorder.
• Subjects must be considered stable, per investigator judgement.
• Subject is willing to abide by the contraception requirements for the duration of the study.

You may not qualify if:

• Subject has a comorbid neuropsychiatric disorder that could interfere with participation in the study.
• Subject poses a current suicide risk as assessed by the Investigator or as confirmed by the baseline Columbia-Suicide Severity Rating Scale by a response of "Yes" to question numbers 4 or 5 with ideation or suicidal behavior occurring in the past 12 months (assessed at Screening and at Visit 2, Day 1).
• Subject has a diagnosis of diabetes or presents with pre-diabetes lab results (hemoglobin A1c ≥6%).
• Subject has a history of use of clozapine or use of long-acting injectable antipsychotic medication within 3 months prior to Screening.
• Subject has a DSM-5 (Diagnostic and Statistical Manual of Mental Disorders-5) diagnosis of moderate to severe alcohol disorder, or moderate to severe substance use disorder, within the 3 months prior to Screening.
• Subject has taken opioid agonists within the 14 days prior to Screening, or has taken long-acting opioid agonist within the 30 days prior to Screening, or has anticipated a need to take opioid medication during the study period (eg, planned surgery, including oral surgery), or has taken opioid antagonists including naltrexone (any formulation) and naloxone within 60 days prior to Screening.
• Subject is unable to swallow oral medications, as assessed by the Investigator.
• Subject has a positive urine drug screen for opioids (assessed at Screening and at Visit 2, Day 1).
• Subject has a positive cotinine test (assessed at Screening and at Visit 2, Day 1).
• Subject has an intellectual disability, as assessed by the Investigator.
• Subject has a history of intolerance or hypersensitivity to olanzapine or opioid antagonists, or any component of the study drug.

Sponsors & Collaborators

• Alkermes, Inc.: lead

Study Sites (2)

Alkermes Investigational Site

Decatur, Georgia, 30030, United States

Location

Alkermes Clinical Investigative Site

Cincinnati, Ohio, 45219, United States

Location

Study Officials

• David McDonnell, MD

  Alkermes, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 26, 2021
• First Posted: August 3, 2021
• Study Start: July 22, 2021
• Primary Completion: August 11, 2023
• Study Completion: August 11, 2023
• Last Updated: November 22, 2023

Record last verified: 2023-11

Data Sharing

• IPD Sharing: Will not share

Locations

US (2)